Compare KNF & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNF | TFX |
|---|---|---|
| Founded | 1917 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | N/A | N/A |
| Metric | KNF | TFX |
|---|---|---|
| Price | $80.63 | $106.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 10 |
| Target Price | $95.88 | ★ $137.11 |
| AVG Volume (30 Days) | 667.2K | ★ 1.0M |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | $3,048,164,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | $8.80 | $9.54 |
| Revenue Next Year | $5.90 | $10.52 |
| P/E Ratio | $30.54 | ★ N/A |
| Revenue Growth | ★ 5.52 | 5.42 |
| 52 Week Low | $58.72 | $100.18 |
| 52 Week High | $105.99 | $180.58 |
| Indicator | KNF | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 46.77 |
| Support Level | $66.88 | $104.03 |
| Resistance Level | $80.48 | $108.95 |
| Average True Range (ATR) | 2.93 | 3.13 |
| MACD | 0.89 | 0.89 |
| Stochastic Oscillator | 92.18 | 70.41 |
Knife River Holding Co is an aggregates-led construction materials and contracting services provider. Its segments include Pacific, Northwest, Mountain, North Central, South, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.